Olivia L. Munns
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olivia L. Munns has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Liam Thomas Ball
School of Chemistry
1 shared publication Richard Herzog
Albert-Ludwigs-Universität Freiburg Albertstraße 21
1 shared publication- Stephen P. Argent
School of Chemistry University of Nottingham Nottingham UK
1 shared publication - Valentin Magné
Université de Toulouse, CNRS, CEMES
1 shared publication
Latest Publications
- Open Access
- 7 August 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
Scalable Synthesis of a Masked Thiophenol as an Air-Stable, Odorless Intermediate to the Aurora Kinase Inhibitor Tozasertib (VX-680)
The use of thiophenols on process scales is fraught with challenges relating to their toxicity, malodor, and air sensitivity. We previously demonstrated that the Ni-catalyzed C–S coupling of aryl iodides and thiourea provides a discovery-scale route to S-aryl isothiouronium salts, which serve as bench stable, odorless, and highly crystalline surrogates of thiophenols. Here, we report the process optimization of this methodology for the synthesis of a key intermediate to kinase inhibitor tozasertib (VX-680). The corollary is a reduction in catalyst loading to 0.5 mol %, elimination of NMP solvent, and introduction of a direct crystallization, giving 95% yield on a 100 g scale.
- 7 August 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
Open AccessScalable Synthesis of a Masked Thiophenol as an Air-Stable, Odorless Intermediate to the Aurora Kinase Inhibitor Tozasertib (VX-680)
The use of thiophenols on process scales is fraught with challenges relating to their toxicity, malodor, and air sensitivity. We previously demonstrated that the Ni-catalyzed C–S coupling of aryl iodides and thiourea provides a discovery-scale route to S-aryl isothiouronium salts, which serve as bench stable, odorless, and highly crystalline surrogates of thiophenols. Here, we report the process optimization of this methodology for the synthesis of a key intermediate to kinase inhibitor tozasertib (VX-680). The corollary is a reduction in catalyst loading to 0.5 mol %, elimination of NMP solvent, and introduction of a direct crystallization, giving 95% yield on a 100 g scale.